2022 U.S. Market Research Report with COVID-19 Forecasts2

Mrunmayee Honrao | July 11, 2022 | 367 views | Read Time : 1 min

2022 U.S
The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further.

The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026.

This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more.

Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries.

This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Spotlight

Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first autologous cellular immunotherapy product, PROVENGE(R) (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN.

OTHER ARTICLES
MEDTECH

How to Choose a Reliable Biotech Clinical Trial Management System?

Article | July 11, 2022

Introduction The medical and life-science industries are experiencing a robust transformation with the increasing prevalence of various types of diseases, including infectious diseases, chronic disorders, and acute conditions around the world. As a result, a significant rise in demand for more effective therapeutic drugs and bionics is being witnessed, leading to a swift increase in the number of clinical trials. For a successful trial, it is important for biotech companies to ensure the data submitted to regulatory bodies regarding clinical trials is accurate, reliable, and definitive from an ethical point of view. A reliable clinical trial management system plays a vital role in collecting, monitoring, and managing clinical data. The availability of high-quality clinical data also helps clinical research institutions make efficient treatment decisions and provide proper patient care. Hence, a number of biotech companies and research organizations are focusing on leveraging innovative clinical trial management solutions to handle a large amount of data, particularly in multi-center trials, and generate reliable, high-quality, and statistically sound data from clinical trials. However, selecting the most appropriate and reliable clinical trial management system is vital for the clinical trial's success. Let's see some of the steps that will assist these firms in choosing the right CTMS. Key Steps for Selecting Right Biotech Clinical Trial Management System Prioritize Study Needs Considering and prioritizing study needs is a crucial step in choosing the most reliable clinical trial management system for biotech companies. Prioritizing helps them to identify a solution that improves the study's quality and removes uncertainty for researchers when faced with difficult choices. Hence, biotech and life-science organizations should choose a clinical trial system that is simple to use, well-organized, and suitably designed to minimize the number of clicks required to complete a task. Select CTMS with Multiple Integrations Integrated clinical trial management systems provide the best value for the companies’ funds as they guarantee the smooth functioning of research protocols. In addition, integrations are necessary to fully understand the importance and advantages of clinical trial management software for ensuring smooth transitions between site management and data collection. Biotech and clinical research should look for CTMS platforms that can integrate with electronic medical record (EMR) platforms and clinical research process content (CRPC) billing grids. This will allow them to use the same billing designations and ensure compliance while minimizing the need for duplicate processes. Ensure System Compliance and Security Clinical research organizations need to adhere to a plethora of complex regulations in order to ensure compliance with one of the most challenging environments of principles, which is information security and privacy. Security and system compliance are vital aspects of choosing the right CTMS solutions for biotech firms as they assist in building trust and form a part of the system’s duties. While selecting CTMS systems, it is essential for companies engaged in clinical research to ensure that these platforms are able to configure both, group and individual permissions, along with having a data backup and recovery plan for hosted systems. This will allow companies to assess the privacy and security implications of research and anticipate complications that may arise in each phase of the project. Assess the Scalability Choosing a scalable CTMS that can accommodate various types of fluctuations and expansions enables biotech and clinical firms to quickly adapt to fast-changing trends and demand spikes while reducing maintenance costs and enhancing user agility. As scalability also means secure and expanded data storage, these businesses should instead use SaaS solutions than manually manage an ever-growing collection of hard drives. The right CTMS ensures accommodating the firm’s availability requirements without incurring the capital costs associated with expanding a physical infrastructure. The Closing Thought A well-executed and successful clinical trial involves multiple stages and processes. Several quality controls and stringent adherence to regulations are essential for the steps, along with efficient cross-departmental processes and procedures. Incorporating the right CTMS paves the way for paperless data collection, regulatory filing, and fiscal management tools for biotech researchers and administrative personnel.

Read More
MEDTECH

Top 3 Biotech Clinical Data Management Trends to Watch in 2022

Article | July 5, 2022

Introduction The administration of medical records and data has advanced significantly during the past few decades. Clinical data management, which was once only a small subset of biotech research organizations, has now developed into a mission-critical, specialized unit. In the late 1990s, electronic data capture (EDC) began to alter the traditional function of clinical data management. After that, the data configuration and management of data queries for the EDC system fell under the purview of clinical data management services. Today, clinical data management is not only responsible for managing the clinical data configuration and data queries but also developing and implementing data administration plans, ensuring data accuracy and completeness, and maintaining optimum data security. In recent years, as digital technologies have gained acceptance around the globe, data has become a vital aspect in decision-making across numerous industries, and the life sciences and biotechnology sectors are no exception. Using data has provided granular insights to biotech organizations, assisting them in creating breakthroughs in drug development and medical research and signifying the importance of clinical trial management systems in these medical verticals. The Biggest Biotech Clinical Data Management Trends to Know About Today The future of clinical data management is contingent upon the implementation of systems and regulations. It is imperative for all organizations participating in a medical or life science trial to have transparent rules in place for sharing and retaining patient data. Also, there is a need to have a standardized format for maintaining these records and documents related to trials. This assists biotech organizations in reducing the chances of ambiguity regarding who owns what kind of data or paperwork at any given time. Over the past couple of years, the focus of the life science and biotechnology industries has shifted towards developing more effective medications and therapies, implementing personalized treatment, and finding cures for diseases such as cancer and AIDS. In response to this, a substantial rise in the number of clinical trials is being witnessed globally. As the number of clinical trials continues to accelerate, the spending on these trials rises as well. In response to this, the worldwide cost of conducting clinical trials is anticipated to reach US$ 49.80 billion in 2022. With the transition of the world from traditional to digital, medical professionals and biotech businesses are increasingly shifting towards adopting high-tech and reliable clinical trial management systems for various applications, starting from diagnosis and clinical trials to patient data documentation. But, what are the future trends in biotechnology clinical data management? Let’s discuss. Cloud-Based Clinical Metadata Repositories Automation is emerging as a new frontier in the biotech clinical data management domain, along with other innovative technologies such as artificial intelligence and machine learning. Because of this, life science establishments are witnessing a huge shift from paper-based documentation toward data-based documentation, which is creating mountains of research, compliance, and clinical data. The growing demand for new and more effective medications and drugs is augmenting the need to expedite clinical trials. This is resulting in an increased number of initiatives aimed at optimizing clinical trial processes to prepare and launch successful trials. However, pharmaceutical and biotechnology laboratories are encountering several challenges in collecting, managing, and analyzing metadata due to its complexities. So, what is the best solution to this problem? The answer to this is cloud-based clinical metadata repositories. Clinical research facilities are leveraging advanced, all-in-one, cloud-based clinical metadata repositories to assist them in centralizing and managing metadata; increasing metadata quality, consistency, and accuracy; and speeding up clinical trial management, documentation, and compliance processes. Shift Towards Digital Solutions Electronic Case Report Form Adequate research and accurate data are crucial for a clinical trial to succeed. Whether developing new drugs, medication, or therapies; conducting life science research; or studying the latest clinical trial systems, it is best to use electronic solutions as it reduces the room for mistakes during the transition of clinical data from paper-based format. Realizing this, biotech organizations are shifting towards using electronic case report forms to speed up record retrieval, improve record security, and cut down on operational costs associated with running clinical trials. The electronic case report form assists in lowering the failure rate of the clinical trial, enhancing efficiency, and optimizing security along with improving clinical trial documentation and productivity, further driving its adoption in the medical space. Electronic Clinical Outcome Assessment Electronic clinical outcome assessment is surfacing as one of the fast-growing future trends in biotechnology. It allows clinical trial facilities to automate data entry and improve the reliability of the collected information. The technology enables clinical trial institutions to automatically record patient-provided information about side effects, symptoms, drug timing, and other aspects during the clinical trial for increased precision. It also helps these institutions analyze the results of medication or therapy in clinical trials and lets clinical researchers use medical technologies like biosensor-enabled devices, self-service applications, and medical wearables for evaluation. Hence, biotech clinical facilities are increasingly deploying advanced electronic clinical outcome assessment systems to ensure adherence to protocols and regulations. Clinical Trial Customization The success of a new drug is determined by numerous factors other than its effectiveness, safety, and creativity of its developers, such as a successful clinical trial. Each clinical trial involves a number of decision-making points, and one wrong choice in any of these aspects can jeopardize the success of the entire endeavor. A crucial component of making well-informed decisions is data management, which is a part of clinical study as a whole. Clinical trial customization is emerging as one of the most prominent biotech clinical trial management trends. Every clinical trial is unique and needs a tailored approach to be successful. With the emergence of the trend of personalized treatment around the globe, biotech and pharmaceutical organizations are adopting innovative customized clinical trial management solutions to accelerate the pace of clinical trials and approvals. This is giving clinical researchers innovative ways to come up with new medicines for patients and streamline the clinical data as per the requirements for faster approvals. What Are the Key Clinical Data Management Challenges Faced by Biotech Companies? Groundbreaking medical interventions are of no use without reliable, accurate, and extensive clinical trial data. Without the data, biotech and pharmaceutical companies will not be able to provide the assurance of safety and efficacy required to bring the medication to market. Regulatory bodies such as the Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and others are putting stricter rules in place to ensure the quality of clinical data. In addition, the fast-changing clinical development environment is creating more obstacles for biotech and medical spaces to ensure the accuracy, standard, and completeness of the clinical trial data. Hence, clinical teams are spending valuable time cleaning up data instead of analyzing it. Time spent trying to figure out issues with clinical trial data is detrimental and expensive but also mission-critical. This is because a small issue in the data can lead to numerous consequences, from small delays to calamitous setbacks, making it necessary to rerun clinical trials. This problem will only get more challenging to address as the volume of data and the types of data sources continue to grow. Here are some of the major clinical data management challenges that biotech firms encounter Standardization of Clinical Metadata Stringent Regulatory Compliance Increased Clinical Trial Complexity Mid-Study Changes Why Are Clinical Data Management Systems Garnering Popularity in the Biotech Industry? With the changing regulatory and clinical landscape, biotech and pharmaceutical companies are facing several obstacles in the management of clinical data and clinical trials. In addition, regulatory agencies are moving toward integrated electronic systems, which is making it more and more important for clinical laboratories to change the format of their submissions. Because of this, several biotech clinical labs are focusing on adopting innovative laboratory solutions, such as biotech clinical data management systems, to meet the need for standardized data inputs and replace all manual ways of working with electronic systems. A clinical data management system establishes the framework for error-free data collection and high-quality data submission, resulting in speedier drug discovery and shorter time-to-market. These solutions are gaining huge traction among biotech and pharmaceutical companies, owing to their ability to effectively manage clinical data, accelerate clinical trials, and ensure compliance. Let’s see some of the features of biotech clinical data management software that are most sought after by life-science companies Controlled, standardized data repository. Centralized data analysis and administration. Reduced operational expenditures for clinical data processes. Enhanced process effectiveness. Superior submission quality Compliance with predefined standards. Clinical Data Management Systems: The Future The role of clinical data management systems is evolving at a rapid pace as the life science and medical industries continue to incorporate digital solutions for diverse operations. These systems are being used in a variety of biotech clinical settings, ranging from clinical data compliance to data science and analytics, to help them analyze large and growing volumes of clinical data. Hence, a number of high-tech medical companies are aiming at integrating innovative technologies, such as artificial intelligence and machine learning, into clinical data management software to automate clinical data management tasks, improve clinical data submission, and enhance data quality. These new biotech clinical management technologies are anticipated to help life science laboratories gain a better understanding of diseases and speed up clinical trials in the coming years. FAQ What is a clinical data management system? A clinical data management system (CDMS) is a tool used in clinical research to track, record, and manage clinical trial data across medical establishments such as biotech laboratories. What are the key functions of the biotech clinical data management system? Some of the key functions of biotech clinical data management system are Documentation of Protocols and Regulations Patient Recruitment Real-time Clinical Study Analytics Reporting Investigator Relationship Management Electronic Visit Report Why is a clinical data management system needed for clinical trials today? A clinical data management system helps shorten the time from drug development to marketing by assisting in the collection of high-quality, statistically sound, and accurate data from clinical trials.

Read More
MEDTECH

Top 10 biotech IPOs in 2019

Article | July 12, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Spotlight

Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first autologous cellular immunotherapy product, PROVENGE(R) (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN.

Related News

RESEARCH, INDUSTRY OUTLOOK

BigHat Biosciences Announces Research Collaboration with Merck

BigHat Biosciences, Inc. | November 30, 2022

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins. Under the collaboration, BigHat and Merck will collaborate to optimize up to three proteins by leveraging BigHat’s platform to synthesize, express, purify, and characterize molecules. Mark DePristo, co-founder and CEO of BigHat, continued, "We are thrilled to be collaborating with Merck's world-class drug development teams to design safer, more effective antibodies for these important therapeutic programs.” The teams have initiated work on the first program and are looking forward to using the power of the complementary skills sets within each research team to generate high-quality lead antibodies. “We are excited to begin this collaboration to advance next-generation antibody therapeutics to patients,” said Elizabeth Schwarzbach, BigHat’s Chief Business Officer. "This agreement with Merck brings us a major step closer to our goal of 3-5 deep collaborations with leading biopharmas to complement our internal therapeutic pipeline." “This agreement with BigHat expands Merck’s strategy of applying AI/ML across our drug discovery capabilities. We look forward to working with the team to leverage BigHat’s technology and expertise in enabling molecular design of novel biologic candidates.” Juan Alvarez, vice president of Biologics Discovery, Merck Research Laboratories About BigHat Biosciences, Inc. BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. They apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is a Series B biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture. BigHat’s broad pipeline of wholly-owned and partnered therapeutic programs span many disparate indications with high unmet need, such as cancer, inflammation, and infectious disease. BigHat has raised over $100M from top investors, including Section 32, a16z, and 8VC.

Read More

RESEARCH

Asia's first industrial insect company, Nutrition Technologies, closes US$20m equity round to launch new products and expand into new markets

Nutrition Technologies | September 19, 2022

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategic partnerships. "Aside from growth in clean-energy, PTT is expanding its portfolio into new businesses corresponding to global trends, sustainability, and social responsibility. We look forward to partnering with Nutrition Technologies to support their next phase of growth. Commercial insect protein production is one of the most important innovations of the past few years, with the potential to disrupt the animal feed and fertiliser sectors and solve multiple issues the world is currently facing. Furthermore, we expect this partnership will provide customers with innovative solutions to revolutionise the agriculture sector as well as improve people's quality of life" Dr. Buranin Rattanasombat, Senior Executive Vice President, Innovation and New Ventures, PTT Public Company Limited. "We are very excited to partner with Nutrition Technologies, an innovative company that has superior technology to produce sustainable protein. We believe insect protein is one of the most important recent solutions to protein production, contributing to solving various environmental issues and addressing several Sustainable Development Goals. We will utilize our business platform and customer network to promote and expand the BSF derived products" said Masahito Uno, GM Life Science Division, Sumitomo Corporation. "Nutrition Technologies fits well in the investment strategy and portfolio of ING Sustainable Investments, as we seek to assist sustainable companies in scaling their operations. Together with our consortium partners we are also keen to support the company in capitalising on various opportunities in the fast-growing European and Asian markets of alternative proteins" Mark Weustink, Head of ING Sustainable Investments "Nutrition Technologies has led the way in delivering black soldier fly solutions at scale and at a price that is competitive on the global markets. It means they are already providing a viable alternative to existing and less sustainable feed options. In achieving that, the team has demonstrated exceptional executional capabilities. Going forward, we have high conviction in their expansion plans" said Hian Goh, Founding Partner, Openspace Ventures. "It is great to welcome our new investors, who collectively bring vast expertise and experience to help us realise our vision. We are also humbled by the continued support provided from our existing shareholders." said Tom Berry, Co-CEO and Co-founder, Nutrition Technologies. The insect sector has gathered increasing attention over the past few years, with the global insect protein market alone estimated to be worth US$343 million in 2021, and expected to grow with a CAGR of 26.49% to reach US$1.3 billion by 2027. As a sustainable solution to help minimise multiple unsustainable practices, the sector as a whole has seen investments totalling nearly US$1 billion, but with multiple technological hurdles, few companies are yet to reach industrial scale, let alone profitability. Global food security has steadily declined for the past few decades and has been significantly tested in recent years through extreme weather events and war. Population growth has fuelled the current 1.2 billion tonnes demand for animal feed ingredients, which has severe environmental consequences both for land and sea. There is a growing protein deficit, with supplies of traditional proteins for animal feed, such as fishmeal and soybean meal, stagnating due to overfishing and deforestation. Meanwhile, organic matter and food waste in landfills are significant contributors of greenhouse gas emissions, and the overuse of chemical fertilisers is severely reducing the productivity and resilience of crucial agricultural soil. "Insects represent a virtually unlimited and untapped pool of biological assets, with huge opportunities for value creation. Tackling food security is only the tip of the iceberg and with our strengthened balance sheet, great partners and best in class IP, we are strategically positioned to lead the next agricultural revolution." said Richard Hayler, CFO, Nutrition Technologies. Since 2015, Singaporean agri-biotech company, Nutrition Technologies, has been creating a commercial replica of the natural decomposition process, using their proprietary growth inoculants and black soldier flies (Hermetia illucens) to turn low-grade crop & food waste into highly sought after animal feed ingredients and biofertilisers. Their two hectare production facility in Johor, Malaysia, bioconverts several hundreds of tonnes of organic waste every week. The facility produces functional proteins and oils, which have bioactive compounds that efficiently improve animal growth performance and health outcomes. Over the past few years Nutrition Technologies has conducted multiple trials of their products on fish, shrimp, poultry, piglets and pets, with significant results. Their novel biofertiliser products improve soil health while naturally increasing plant resistance to disease, reducing the need for chemical pesticides. The 165-strong team has been scaling up their operations and selling their products into both domestic and regional markets. "We are increasing production to meet market demand and providing essential ingredients to the domestic agricultural sector as well as boosting exports through shipping our products to Korea, Japan, Indonesia, Thailand, Vietnam, Philippines and Chile. We will also commence shipments to the UK and EU very soon." said Nick Piggott, Co-CEO and Co-founder, Nutrition Technologies. Nutrition Technologies' production facilities are a result of over seven years of R&D and their strategic location in the tropics helps to optimise productivity and lower costs. Their proprietary technologies and vertical insect production system are designed to capitalise on the low-energy benefits and suitability of a tropical climate. Their team developed the entire production system, which uses some bespoke automated equipment to ensure strict biosafety, zero-waste and strong unit economics. Through avoided emissions, their products have great potential to help meet global climate change targets. Nutrition Technologies has been doubling down on its success in commercialising insect-microbe systems and their approach to protecting that intellectual property has been lauded by IP experts and publications. "We have had some incredibly exciting breakthroughs over the past two years. Following successful additions to our patent portfolio, we will launch two new revolutionary biological products to the fertiliser market that will address some of the region's greatest challenges in crop productivity." said Martin Zorrilla, Nutrition Technologies.

Read More

INDUSTRIAL IMPACT

Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab

Agilent Technologies | December 01, 2022

cevel sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science. ‘Angel’ level sponsorship provides Agilent access to even more strategic counsel from My Green Lab in support of its sustainability activities and expertise that can be shared with customers. Agilent is also the proud sponsor of the My Green Lab Certification program – considered the gold standard for laboratory sustainability best practices. As a good citizen and role model for customers, Agilent is working to ensure its on-site customer demonstration laboratories globally are Green Lab Certified and have already achieved highest level certification for Waldbronn, Germany, Cheadle, UK, and Santa Clara, US sites. “Sustainability and environmental, social, and governance standards are central to our mission to advance the quality of life, and our sponsorship of My Green Lab helps us to drive this forward. Being an ‘Angel’ level sponsor will further cultivate our knowledge of creating sustainable green labs, which we can share with our customers globally and support them on their sustainability journey.” Darlene Solomon, senior vice president, and chief technology officer at Agilent The Green Lab Certification from My Green Lab is recognized by the United Nations Race to Zero campaign as a key measure of progress for pharmaceutical and medical technology companies toward a zero-carbon future. It indicates that a lab has achieved strong sustainability practices in energy use, water consumption, recycling, and waste production. About Agilent Technologies Agilent Technologies Inc. is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated of $6.85 billion in fiscal 2022 and employs 18,000 worldwide.

Read More

RESEARCH, INDUSTRY OUTLOOK

BigHat Biosciences Announces Research Collaboration with Merck

BigHat Biosciences, Inc. | November 30, 2022

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins. Under the collaboration, BigHat and Merck will collaborate to optimize up to three proteins by leveraging BigHat’s platform to synthesize, express, purify, and characterize molecules. Mark DePristo, co-founder and CEO of BigHat, continued, "We are thrilled to be collaborating with Merck's world-class drug development teams to design safer, more effective antibodies for these important therapeutic programs.” The teams have initiated work on the first program and are looking forward to using the power of the complementary skills sets within each research team to generate high-quality lead antibodies. “We are excited to begin this collaboration to advance next-generation antibody therapeutics to patients,” said Elizabeth Schwarzbach, BigHat’s Chief Business Officer. "This agreement with Merck brings us a major step closer to our goal of 3-5 deep collaborations with leading biopharmas to complement our internal therapeutic pipeline." “This agreement with BigHat expands Merck’s strategy of applying AI/ML across our drug discovery capabilities. We look forward to working with the team to leverage BigHat’s technology and expertise in enabling molecular design of novel biologic candidates.” Juan Alvarez, vice president of Biologics Discovery, Merck Research Laboratories About BigHat Biosciences, Inc. BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. They apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is a Series B biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture. BigHat’s broad pipeline of wholly-owned and partnered therapeutic programs span many disparate indications with high unmet need, such as cancer, inflammation, and infectious disease. BigHat has raised over $100M from top investors, including Section 32, a16z, and 8VC.

Read More

RESEARCH

Asia's first industrial insect company, Nutrition Technologies, closes US$20m equity round to launch new products and expand into new markets

Nutrition Technologies | September 19, 2022

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategic partnerships. "Aside from growth in clean-energy, PTT is expanding its portfolio into new businesses corresponding to global trends, sustainability, and social responsibility. We look forward to partnering with Nutrition Technologies to support their next phase of growth. Commercial insect protein production is one of the most important innovations of the past few years, with the potential to disrupt the animal feed and fertiliser sectors and solve multiple issues the world is currently facing. Furthermore, we expect this partnership will provide customers with innovative solutions to revolutionise the agriculture sector as well as improve people's quality of life" Dr. Buranin Rattanasombat, Senior Executive Vice President, Innovation and New Ventures, PTT Public Company Limited. "We are very excited to partner with Nutrition Technologies, an innovative company that has superior technology to produce sustainable protein. We believe insect protein is one of the most important recent solutions to protein production, contributing to solving various environmental issues and addressing several Sustainable Development Goals. We will utilize our business platform and customer network to promote and expand the BSF derived products" said Masahito Uno, GM Life Science Division, Sumitomo Corporation. "Nutrition Technologies fits well in the investment strategy and portfolio of ING Sustainable Investments, as we seek to assist sustainable companies in scaling their operations. Together with our consortium partners we are also keen to support the company in capitalising on various opportunities in the fast-growing European and Asian markets of alternative proteins" Mark Weustink, Head of ING Sustainable Investments "Nutrition Technologies has led the way in delivering black soldier fly solutions at scale and at a price that is competitive on the global markets. It means they are already providing a viable alternative to existing and less sustainable feed options. In achieving that, the team has demonstrated exceptional executional capabilities. Going forward, we have high conviction in their expansion plans" said Hian Goh, Founding Partner, Openspace Ventures. "It is great to welcome our new investors, who collectively bring vast expertise and experience to help us realise our vision. We are also humbled by the continued support provided from our existing shareholders." said Tom Berry, Co-CEO and Co-founder, Nutrition Technologies. The insect sector has gathered increasing attention over the past few years, with the global insect protein market alone estimated to be worth US$343 million in 2021, and expected to grow with a CAGR of 26.49% to reach US$1.3 billion by 2027. As a sustainable solution to help minimise multiple unsustainable practices, the sector as a whole has seen investments totalling nearly US$1 billion, but with multiple technological hurdles, few companies are yet to reach industrial scale, let alone profitability. Global food security has steadily declined for the past few decades and has been significantly tested in recent years through extreme weather events and war. Population growth has fuelled the current 1.2 billion tonnes demand for animal feed ingredients, which has severe environmental consequences both for land and sea. There is a growing protein deficit, with supplies of traditional proteins for animal feed, such as fishmeal and soybean meal, stagnating due to overfishing and deforestation. Meanwhile, organic matter and food waste in landfills are significant contributors of greenhouse gas emissions, and the overuse of chemical fertilisers is severely reducing the productivity and resilience of crucial agricultural soil. "Insects represent a virtually unlimited and untapped pool of biological assets, with huge opportunities for value creation. Tackling food security is only the tip of the iceberg and with our strengthened balance sheet, great partners and best in class IP, we are strategically positioned to lead the next agricultural revolution." said Richard Hayler, CFO, Nutrition Technologies. Since 2015, Singaporean agri-biotech company, Nutrition Technologies, has been creating a commercial replica of the natural decomposition process, using their proprietary growth inoculants and black soldier flies (Hermetia illucens) to turn low-grade crop & food waste into highly sought after animal feed ingredients and biofertilisers. Their two hectare production facility in Johor, Malaysia, bioconverts several hundreds of tonnes of organic waste every week. The facility produces functional proteins and oils, which have bioactive compounds that efficiently improve animal growth performance and health outcomes. Over the past few years Nutrition Technologies has conducted multiple trials of their products on fish, shrimp, poultry, piglets and pets, with significant results. Their novel biofertiliser products improve soil health while naturally increasing plant resistance to disease, reducing the need for chemical pesticides. The 165-strong team has been scaling up their operations and selling their products into both domestic and regional markets. "We are increasing production to meet market demand and providing essential ingredients to the domestic agricultural sector as well as boosting exports through shipping our products to Korea, Japan, Indonesia, Thailand, Vietnam, Philippines and Chile. We will also commence shipments to the UK and EU very soon." said Nick Piggott, Co-CEO and Co-founder, Nutrition Technologies. Nutrition Technologies' production facilities are a result of over seven years of R&D and their strategic location in the tropics helps to optimise productivity and lower costs. Their proprietary technologies and vertical insect production system are designed to capitalise on the low-energy benefits and suitability of a tropical climate. Their team developed the entire production system, which uses some bespoke automated equipment to ensure strict biosafety, zero-waste and strong unit economics. Through avoided emissions, their products have great potential to help meet global climate change targets. Nutrition Technologies has been doubling down on its success in commercialising insect-microbe systems and their approach to protecting that intellectual property has been lauded by IP experts and publications. "We have had some incredibly exciting breakthroughs over the past two years. Following successful additions to our patent portfolio, we will launch two new revolutionary biological products to the fertiliser market that will address some of the region's greatest challenges in crop productivity." said Martin Zorrilla, Nutrition Technologies.

Read More

INDUSTRIAL IMPACT

Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab

Agilent Technologies | December 01, 2022

cevel sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science. ‘Angel’ level sponsorship provides Agilent access to even more strategic counsel from My Green Lab in support of its sustainability activities and expertise that can be shared with customers. Agilent is also the proud sponsor of the My Green Lab Certification program – considered the gold standard for laboratory sustainability best practices. As a good citizen and role model for customers, Agilent is working to ensure its on-site customer demonstration laboratories globally are Green Lab Certified and have already achieved highest level certification for Waldbronn, Germany, Cheadle, UK, and Santa Clara, US sites. “Sustainability and environmental, social, and governance standards are central to our mission to advance the quality of life, and our sponsorship of My Green Lab helps us to drive this forward. Being an ‘Angel’ level sponsor will further cultivate our knowledge of creating sustainable green labs, which we can share with our customers globally and support them on their sustainability journey.” Darlene Solomon, senior vice president, and chief technology officer at Agilent The Green Lab Certification from My Green Lab is recognized by the United Nations Race to Zero campaign as a key measure of progress for pharmaceutical and medical technology companies toward a zero-carbon future. It indicates that a lab has achieved strong sustainability practices in energy use, water consumption, recycling, and waste production. About Agilent Technologies Agilent Technologies Inc. is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated of $6.85 billion in fiscal 2022 and employs 18,000 worldwide.

Read More

Events